, Tracking Stock Market Picks
Enter Symbol:
Avanir Pharmaceuticals (AVNR) [hlAlert]

up 290.78 %

Avanir Pharmaceuticals (AVNR) rated Buy with price target $16 by Summer Street Research

Posted on: Monday,  Jul 8, 2013  9:25 AM ET by Summer Street Research

Summer Street Research rated Buy Avanir Pharmaceuticals (NASDAQ: AVNR) on 07/08/2013, when the stock price was $4.34. Since
then, Avanir Pharmaceuticals has gained 290.78% as of 01/12/2015's recent price of $16.96.
If you would have followed this Summer Street Research's recommendation on AVNR, you would have gained 290.78% of your investment in 553 days.

Avanir Pharmaceuticals is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company?s product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The Company?s first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA).

Summer Street Research s is an institutional equity research and trading firm that focuses exclusively on the healthcare sector. Our mission is to help our clients maximize returns by providing the best healthcare research, ideas, and investment opportunities. In recognition of our excellence in research, Summer Street Research Partners was the 2005 winner of Institutional Investor's "Best Independents" award for both biotechnology and specialty pharmaceutical research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/8/2013 9:25 AM Buy
4.34 16.00
as of 12/13/2013
1 Week down  -34.56 %
1 Month down  -36.32 %
3 Months down  -30.39 %
1 YTD down  -34.56 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy